文献速递治疗药物监测与药物基因组学

药物遗传学对他汀类药物治疗血脂异常疗效与安全性的影响

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.
PubMed 文献 · Pharmacotherapy · 2017-08-23

本文综述了药物遗传学对他汀类药物疗效与安全性个体差异的影响。许多基因多态性可能通过改变蛋白结构或表达,影响他汀的吸收、分布、代谢、排泄及药效通路,但多数研究样本小或为回顾性,且结果不一致,与心血管事件等患者结局的明确关联尚未确立。本文汇总了当前可能具有临床相关性的证据,以辅助个体化他汀治疗。

要点

  • 基因多态性可影响他汀的药代与药效参数,但多数关联与患者结局的关系尚未确立。
  • 现有研究常样本小或为回顾性,结果存在冲突,需更多基于结局的研究验证。
  • 已汇总的临床相关证据可辅助临床医生为需他汀治疗的患者提供个体化用药。

核心结论

  • 许多基因多态性可能与他汀疗效和安全性个体差异相关,但除少数外,与心血管事件等患者结局的明确关系尚未确立。

研究设计与样本

  • 本文为综述,基于现有药物遗传学证据总结他汀疗效与安全性相关的基因关联及临床相关性。

主要发现

  • 基因多态性可能改变编码蛋白的结构或表达,影响脂质和他汀的吸收、分布、代谢、排泄及药效相关通路。
  • 许多研究探讨了他汀药代与药效参数的变异,但据作者所知,少有研究确立基因多态性与心血管事件等患者结局的明确关系。
  • 现有研究常样本小或为回顾性,结果可能相互冲突,但可为未来确证性研究提供方向。

临床怎么用

  • 汇总的临床相关证据可辅助临床医生为需他汀治疗的患者提供个体化药物治疗。

局限性

  • 目前可用的研究常样本小或为回顾性,且结果可能相互冲突。
  • 与患者结局(如心血管事件)的明确关系尚未确立,需更多基于结局的研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Interindividual variability in response to 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, or statins, with regard to both efficacy and safety is an obvious target for pharmacogenetic research. Many genes have been identified as possible contributors to variability in statin response and safety. Genetic polymorphisms may alter the structure or expression of coded proteins, with potential impacts on lipid and statin absorption, distribution, metabolism, and elimination as well as response pathways related to the pharmacologic effect. Many studies have explored the variation in statins' pharmacokinetic and pharmacodynamic parameters; however, to our knowledge, few have established definitive relationships between the genetic polymorphisms and patient outcomes, such as cardiovascular events. In this review article, we provide a statin-based summary of available evidence describing pharmacogenetic associations that may be of clinical relevance in the future. Although currently available studies are often small or retrospective, and may have conflicting results, they may be useful in providing direction for future confirmatory studies and may point to associations that could be confirmed in the future when more patient outcomes-based studies are available. We also summarize the clinically relevant evidence currently available to assist clinicians with providing personalized pharmacotherapy for patients requiring statin therapy.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Maxwell WD, Ramsey LB, Johnson SG, et al. Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia. Pharmacotherapy. 2017. PMID: 28672099. doi:10.1002/phar.1981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。